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Abstract During prolonged hypoxic conditions, endothe-
lial cells change their gene expression to adjust to the low
oxygen environment. This process is mainly regulated by
the hypoxia-inducible factors, HIF-1a and HIF-2a.
Although endothelial cells do not form sprouts during
prolonged hypoxic culturing, silencing of HIF-2a partially
restores sprout formation. The present study identifies
novel HIF-2a-target genes that may regulate endothelial
sprouting during prolonged hypoxia. The gene expression
profile of primary human microvascular endothelial cells
(hMVECs) that were cultured at 20 % oxygen was com-
pared to hMVECs that were cultured at 1 % oxygen for
14 days by using genome-wide RNA-sequencing. The
differentially regulated genes in hypoxia were compared to
the genes that were differentially regulated upon silencing
of HIF-2a in hypoxia. Surprisingly, KEGG pathway anal-
ysis showed that metabolic pathways were enriched within
genes upregulated in response to hypoxia and enriched
within genes downregulated upon HIF-2a silencing.
Moreover, 51 HIF-2a-regulated genes were screened for
their role in endothelial sprouting in hypoxia, of which four
genes ARRDC3, MME, PPARG and RALGPS2 directly
influenced endothelial sprouting during prolonged hypoxic
culturing. The manipulation of specific downstream targets
of HIF-2a provides a new, but to be further evaluated,
perspective for restoring reduced neovascularization in
several pathological conditions, such as diabetic ulcers or
other chronic wounds, for improvement of vascularization
of implanted tissue-engineered scaffolds.
Keywords Angiogenesis  Hypoxia  HIF-2a  Genome-
wide RNA-sequencing
Introduction
Angiogenesis, the formation of new blood vessels through
endothelial sprouting, is important for tissue growth,
development and proper wound healing. Nevertheless,
angiogenesis is associated with several pathological con-
ditions, such as tissue ischemia, solid tumors and adult
macular degeneration of the eye [1]. Usually, these disor-
ders are accompanied by loss of adequate blood supply or
enhanced metabolic demand, leading to reduced oxygen
tension (hypoxia) in the tissue. Not surprisingly, hypoxia is
considered to be one of the most potent initiators of
angiogenesis in vitro and in vivo [2–4] through stabiliza-
tion of the transcription factor hypoxia-inducible factor-1a
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(HIF-1a) and subsequent induction of vascular endothelial
growth factor (VEGF) [5, 6]. Nonetheless, in chronic
hypoxic tissues often a resistance to induction of neovas-
cularization is observed [3, 7–11] and limited expression of
HIF-1 has been observed in chronic hypoxic human leg
tissue [12]. Therefore, there is a need of stimulating neo-
vascularization and temporarily overcoming the endoge-
nous inhibitory factors that prevent induction of
angiogenesis in severely hypoxic tissues.
Despite the progress in understanding the mechanisms
and factors regulating angiogenesis [13, 14], the effects of
long-term hypoxia on angiogenesis regulation and in par-
ticular the behavior of endothelial cells are still poorly
understood. Hypoxia rapidly induces large amounts of
VEGF-A via HIF-1 activation in all tissue cells, thus sup-
plying a major angiogenesis-inducing factor in the envi-
ronment. It activates VEGF receptors on the endothelium
which induce proliferation and—often stimulated by
additional inflammatory factors—cell migration and inva-
sion. However, the transcriptional response of endothelial
cells is more complicated and involves—together with
additional factors—the involvement of HIF-1a and HIF-
2a, which display a partly different spectrum of activation.
HIF-1a has been studied extensively and induces mainly
tortuous and leaky newly formed vascular structures that
are not adequately perfused [15, 16], while HIF-2a
(EPAS1), which is abundantly expressed in endothelial
cells, induces stabilization of endothelial microvessels,
and—in lung microvessels—improves endothelial barrier
function [17]. Indeed, endothelial-specific deletion of HIF-
2a pointed to a role of HIF-2a in the regulation of angio-
genesis in mice [18, 19], which was suggested to occur
through the induction of the Dll4/Notch signaling pathway.
These data suggest that the endothelial cell has its own
program to respond adequately to hypoxia, i.e., in such a
way that finally a mature, sealed and stabilized new
microvascular network is formed. Excess of HIF-1a
response, as observed in many tumors, leads to abundant
tortuous but not or suboptimal functioning microvessels.
As the activation of HIF-1a and HIF-2a is in part transient
and HIF-2a tends to be longer expressed, the balance
between sprouting and stabilization may shift during pro-
longed hypoxia. This may underlie our previous observa-
tion that prolonged hypoxia reduced the ability of
endothelial cells to form sprouts. This was partly related to
a reduction of urokinase–plasminogen activator generation,
which reduces pericellular proteolysis by the uPA/
uPAR/plasmin pathway and—independently—could be
partially relieved by HIF-2a si-RNA [20]. However, the si-
HIF-2a-dependent restoration of sprouting in this study
occurred independent of Dll4/Notch signaling.
The current study investigates which genes and path-
ways are differentially regulated in prolonged hypoxia and
downstream of HIF-2a in conditions that were previously
shown to be favorable for induction of endothelial tubules,
i.e., hMVECs seeded on a 3D-fibrin matrix and stimulated
by VEGF-A/TNFa [20, 21]. Many hypoxia-responsive
genes have been identified using microarrays in different
tumor cell lines [22–28] and human endothelial cells
[4, 29]. However, only short-term hypoxia (16–72 h) under
basal conditions was evaluated, but not prolonged hypoxic
conditions (14 days). Therefore, we studied gene expres-
sion after long-term hypoxia and with and without silenc-
ing of HIF-2a. By using genome-wide RNA-sequencing,
51 genes were identified in VEGF-A/TNFa-stimulated
cells that were regulated in a reversed way in hypoxia or by
HIF-2a silencing and were screened for their ability to




The study was executed in accordance with the Declaration
of Helsinki and was approved by the University Human
Subjects Committee of the VU University Medical Center.
Written informed consent was obtained from all donors in
accordance with the institutional guidelines. Human
microvascular endothelial cells (hMVECs) were isolated
from foreskin, kindly provided by the Department of
Dermatology (VUmc, Amsterdam), cultured and charac-
terized (CD31, vWF, Ulex europaeus lectin-1 binding, VE-
cadherin) as previously described [30, 31]. hMVECs were
cultured on 1 % gelatin-coated culture plates in culture
medium consisting of Medium 199 supplemented with
100 U/mL penicillin and 100 mg/mL streptomycin (p/s),
2 mM L-glutamine (all Lonza, Verviers, Belgium), 5 U/mL
heparin (Leo Pharmaceutical Products, Weesp, The
Netherlands), endothelial cell growth factor (ECGF, crude
extract from bovine brain), 10 % heat-inactivated human
serum (HSi, Life Technologies) and 10 % heat-inactivated
newborn calf serum (NBCSi, Lonza). Medium was chan-
ged every 48 h. Confluent cells were washed with 0.5 mM
EDTA (Merck Millipore) in HBSS, trypsinized (0.05 %
trypsin in EDTA/HBSS, both Lonza) and seeded in a 1:3
density. Cells were cultured at 37 C in a water-saturated
atmosphere of 95 % air and 5 % CO2. hMVECs were used
until passage 10.
Hypoxic cell culture
Hypoxic cell culture conditions were maintained inside a
custom designed hypoxic workstation (T.C.P.S., Rotselaar,
Belgium), with a CO2 and O2 controlled (via injection of
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N2), humidified incubator (Sanyo, Etten-leur, The Nether-
lands), placed inside a T4 glovebox (Jacomex, Dagneux,
France) equipped with an O2X1 oxygen transmitter (GE
Panametrics, Billerica, USA). The oxygen concentration
inside the incubator was continuously monitored with an
internal zirconia sensor and periodically checked with O2
test tubes (Drager Safety, Zoetermeer, The Netherlands).
To prevent re-oxygenation during hypoxic culture, all
media and buffers were preincubated for 4 h before use.
For the long-term hypoxic culture of hMVECs, isolates
were cultured for 2 passages (*14 days) inside the
hypoxic workstation.
In vitro tube formation assay
3D human tube formation was evaluated as previously
described [21]. 2 mg/mL fibrinogen (Stago bnl, Leiden, The
Netherlands) was dissolved in M199 medium ? p/s.
Thrombin (0.05 U/mL) was added to the fibrinogen solution
and 100 lL was immediately added to wells of a 96-well
plate. For polymerization, plates were incubated for 1 h at
room temperature followed by 1 h at 37 C. Thrombin was
inactivated by addition of serum-supplemented culture
(SSC) medium consisting of Medium 199 with p/s supple-
mented with 10 % HSi, 10 % NBCSi and 2 mM L-glu-
tamine. hMVECs, precultured for 14 days at 20 % or 1 %
oxygen, were seeded in a confluent density on top of the
fibrin matrices. After 24 h, and subsequently at 48-h inter-
vals, the hMVECs were stimulated with SSC medium with
10 ng/mL tumor necrosis factor-a (TNFa, Sigma, St Louis,
USA) and 25 ng/mL vascular endothelial growth factor
(VEGF, Invitrogen, Carlsbad, USA) or 10 ng/mL TNFa
and 10 ng/mL fibroblast growth factor-2 (FGF-2, Prepro-
tech, London, UK). The experiments were terminated by
fixation with 2 % paraformaldehyde/HBSS for 2 h at room
temperature. The formation of tube-like structures from
hMVECs into the fibrin matrices was analyzed by phase
contrast microscopy and Optimas image analysis software.
Transfection with si-RNA
3 9 105 hMVECs were transfected with 25 nM of indi-
cated si-RNA (si-HIF-2a was custom designed and
obtained from Qiagen (Venlo, The Netherlands)) and 51
genes for screening were ordered as Cherry-pick Library
from GE Dharmacon (Lafayette, CO) using DharmaFECT
transfection reagent Type 1. In short, hMVECs were
transfected with 2 mL 10 % HSi/M199 containing 2.5 lL
DharmaFECT transfection reagent Type 1 and si-RNA.
18 h after transfection, cells were refreshed with culture
medium to start the experiment. In prolonged hypoxia
experiments, the procedure was performed continuously in
a 1 % oxygen atmosphere.
RNA isolation and genome-wide RNA-sequencing
hMVECs were cultured for 14 days at normoxic or hypoxic
conditions. Upon confluency, cells were starved for 18 h in
SSC medium and afterward stimulated with VEGF (10 ng/
mL) and TNFa (10 ng/mL) in SSC medium for 24 h. Total
RNA was isolated by using the RNeasy Mini kit according
to manufacturer’s protocol without the DNAse treatment
(Qiagen).
4 lg of RNA/sample with an RIN C 9.8 was subjected to a
double round of poly-A mRNA purification, fragmented, and
primed for cDNA library synthesis using the TruSeq RNA
sample preparation kit (FC-122-1001). All procedures were
done according to the manufacturer’s instructions (Illumina).
Following validation (Agilent 2100 Bioanalyzer, DNA High
Sensitivity) and normalization (AUC 200- to 500-bp frag-
ments), samples were clustered (TruSeq paired-end cluster kit
v3-cBot-HS,PE-401-3001) followedbypaired-end sequencing
(100 bp; TruSeqSBSkit v3-HS200 cycles, FC-401-3001) on a
HiSeq2500. RNA-Seq reads were aligned to the preassembled
reference genome (Illumina iGenome, data source UCSC
assemblyhg19; February 2009) usingTopHat (version2.0.9) in
combination with Bowtie (version 2.1.0) and SAMtools (ver-
sion0.1.18)using thedefault settings [32].Transcript assembly,
abundance estimation (defined as fragments per kilobase of
exon per million fragments mapped; FPKM) and differential
expression were performed by sequential analysis of TopHat
output (accepted_hits.bam). For this, transcripts were assem-
bled using Cufflinks (version 2.1.1) under conditions (RABT
assembly) [33] permitting the identification of novel unanno-
tated transcripts (transcripts.gtf) and with correction for frag-
ment bias to account for biases in library preparation [34]. The
assemblies to be compared were merged (Cuffmerge), gener-
ating a transcript index (merged.gtf). Subsequently, differential
analysis of significant changes in transcript expression, splicing
and promoter use was performed (Cuffdiff) in the different
transfection couples (e.g., hypoxia vs. normoxia).
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR)
was performed using identical RNA as used for the genome-
wide RNA-sequencing. Copy DNA (cDNA) was synthesized
of 1 lg RNA using the Cloned AMV First Strand cDNA
Synthesis Kit from Invitrogen with poly(T)primers. b-2-mi-
croglobulin was used as the endogenous reference gene. To
measure gene expression, qRT-PCR was performed in
duplicate wells using SYBR Green in an ABI 7500 sequence
detection system (Applied Biosystems, Foster City, USA).
Briefly, 10 lLmix was prepared using 20 ng cDNA, 100 nM
forward primer, 100 nM reverse primer and MESA Green
QPCRMastermix Plus for Sybr Assay (Eurogentec, Seraing,
Belgium). Protocol: 2 min 50 C, 10 min95 Cand 40 cycles
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(0:15 min 95 C, 1:00 min 60 C) and dissociation curve.
Relative expression levels of target genes (see also Supple-
mentaryTable 1)were calculatedwith the referencegeneb-2-
microglobulin with the comparative Cq method, as described
by Wong et al. [35].
Tube formation screening
Four independent hMVEC donors were cultured in nor-
moxia until confluency, pooled together and seeded on top
of 3D fibrin matrices. The hMVECs were transfected with
specific si-RNA against the individual genes 4 h after
seeding and 18 h later stimulated with VEGF-A/TNFa and
transferred to hypoxia. Seven days after stimulation with
VEGF-A/TNFa, two researchers evaluated the number of
sprouts independently by eye and only the genes that were
scored as more or less sprouts compared with the scram-
bled control by both researchers were selected for further
investigation. In addition, invading cells and the formation
of tubular structures of endothelial cells in the 3D fibrin
matrix were analyzed by phase contrast microscopy. The
total length of tube-like structures of triplicate wells was
measured using 4 randomly chosen semi-dark field pic-
tures/well using a Nikon FXA microscope equipped with a
monochrome CCD camera (MX5). After threshold setting
and skeletonization, the sprout formation was expressed as
mm/cm2 using Optimas image analysis software (Adept
Turnkey, Sydney, Australia).
Statistical analysis
Statistical analysis was performed using one-way ANOVA
or TWO-way ANOVA with Bonferroni post hoc test.
Numbers of replicates and significant P values are indi-
cated in the text or figures. P\ 0.05 was considered sig-
nificant. Results are shown as mean ± SEM or ±range.
Statistical analysis on genome-wide RNA-sequencing data
was performed using significance analysis of microarrays
(SAM) [36]. Genes that were expressed at significantly dif-
ferent levels were defined by a FDR of\5 % and fold change
[1.5. For visualization of protein–protein interactions and
pathway analysis (Kyoto Encyclopedia of Genes and Gen-
omes (KEGG) [37], STRING10 analysis was used [38].
Results
HIF-2a regulates endothelial sprouting in prolonged
hypoxia
Endothelial cells formed sprouts into a 3D fibrin matrix
under normoxic conditions within 7 days upon stimulation
Fig. 1 Prolonged hypoxia
inhibits endothelial sprouting
into 3D fibrin matrices.
hMVECs were precultured at
1 % or 20 % O2 for 14 days
before seeded on top of 3D
fibrin matrices. Subsequently,
the hMVECs were stimulated
with the combination of VEGF-
A/TNFa (n = 5 donors in 7
experiments) either at 20 % or
1 % O2 (each in triplo). a–
c Representative photographs
are shown of hMVECs 7 days
after seeding and stimulation
with VEGF-A/TNFa. The scale
bars represent 1 mm.
Photographs are focused on the
sprouts. d Tube length was
quantified by using Optimas
software and expressed as
percentage of 20 % O2 with
SEM. For statistical analysis,
one-way ANOVA with
Bonferroni post hoc test was
used (*p\ 0.05; ***p\ 0.001)
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with VEGF-A/TNFa. Sprout formation was decreased
when the assay was performed under hypoxic conditions
for 7 days (20 % O2 ? 1 % O2) (Fig. 1), similarly as we
previously showed [20]. Furthermore, when hMVECs were
precultured for 14 days in hypoxic conditions (1 % O2/
94 % N2/5 % CO2) without reoxygenation, sprout forma-
tion was severely hampered (Fig. 1), independent of cell
proliferation [20]. Silencing HIF-2a with si-RNA partially
restored endothelial sprouting in hypoxia and increased
sprout formation in normoxia, indicating an inhibitory role
of HIF-2a during sprout formation by prolonged hypoxic
and normoxic cultured hMVECs (showed below).
Identifying oxygen-regulated genes and pathways
In order to identify the underlying HIF-2a mechanisms and
target genes that may be involved in the inhibition of the
VEGF-A/TNFa-induced endothelial sprouting during pro-
longed hypoxia, the endothelial transcriptome was
explored. Similar culture conditions were used as the
in vitro 3D tube formation assay, e.g., 14 days of normoxic
or hypoxic preculturing followed by stimulation with
VEGF-A/TNFa.
Gene expression profiling of hMVEC cultures from four
independent donors was performed by genome-wide RNA-
sequencing analysis, and the Tuxedo pipeline with default
settings [32] was used. Data were analyzed as paired using
SAM. The individual donors expressed between 12,000
and 13,000 known genes. In total, 2335 genes were sig-
nificantly (FDR\ 5 %) differentially regulated after 24-h
stimulation with VEGF-A/TNFa in hypoxia-precultured
hMVECs compared with normoxia-precultured hMVECs.
Of these 2335 genes, 501 upregulated and 333 downregu-
lated genes had an absolute fold change of[1.5. The top 25
most upregulated and top 25 most downregulated genes in
prolonged hypoxia, ranked on basis of fold change, are
shown in Table 1. These genes include PHD3 (EGLN3),
HIF-3a (HIF3A) and GLUT1 (SLC2A1), which are known
Table 1 Top 25 genes with significantly induced or repressed gene expression in hypoxia-precultured hMVECs after VEGF-A/TNFa stimulation
Upregulated in Hypoxia Downregulated in Hypoxia
Gene Gene ID Fold Change Gene Gene ID Fold Change
1 EGLN3 NM_022073.3 106.8 1 KYNU NM_003937.2 0.07
2 TIMP4 NM_003256.3 25.9 2 RRM2 NM_001165931.1 0.11
3 PPFIA4 NM_001304331.1 22.9 3 MYBL2 NM_002466.3 0.13
4 PDE4C NM_000923.4 15.0 4 RGS5 NM_003617.3 0.15
5 SLC8A3 NM_033262.4 11.3 5 IGF1 NM_001111283.2 0.16
6 HIF3A NM_152794.3 11.1 6 MKI67 NM_002417.4 0.18
7 MIR210 NR_029623.1 7.9 7 CXorf36 NM_176819.3 0.18
8 ANKRD37 NM_181726.3 7.4 8 TOP2A NM_001067.3 0.19
9 SLC2A1 NM_006516.2 7.3 9 CDC45 NM_001178010.2 0.19
10 VAT1L NM_020927.2 7.1 10 HMOX1 NM_002133.2 0.19
11 SERTAD4 NM_019605.3 7.0 11 GINS2 NM_016095.2 0.21
12 IGFBP5 NM_000599.3 7.0 12 NDC80 NM_006101.2 0.22
13 C1orf133 NW_011332687.1 6.9 13 PKMYT1 NM_004203.4 0.23
14 PPP1R3G NM_001145115.2 6.7 14 MFSD2A NM_001136493.2 0.23
15 PPARG NM_138712.3 6.5 15 CYP2S1 NM_030622.7 0.24
16 CA2 NM_000067.2 6.5 16 CDK1 NM_001786.4 0.24
17 PIM1 NM_001243186.1 6.0 17 SKA1 NM_001039535.2 0.24
18 COL1A2 NM_000089.3 6.0 18 FAM83D NM_030919.2 0.25
19 MT1M NM_176870.2 5.9 19 AURKB NM_004217.3 0.26
20 F2RL3 NM_003950.2 5.8 20 NUF2 NM_145697.2 0.27
21 ST8SIA6 NM_001004470.1 5.7 21 NID2 NM_007361.3 0.27
22 KCTD16 NM_020768.3 4.9 22 DLGAP5 NM_014750.4 0.28
23 LIMCH1 NM_014988.3 4.7 23 CDCA2 NM_152562.3 0.28
24 SHH NM_000193.3 4.5 24 CEP55 NM_018131.4 0.28
25 DACT1 NM_016651.5 4.5 25 PRRX1 NM_006902.4 0.29
The relative gene expression was compared with the gene expression of hMVECs precultured in normoxia and stimulated with VEGF-A/TNFa
(n = 4 independent donors)
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to be upregulated in hypoxia in different cell types
including endothelial cells [4, 22–24, 29, 39]. Even though
VEGF-A was not present within the top 25 genes, it was
significantly upregulated in hypoxia (3.5-fold). The list of
all oxygen-regulated genes can be found in Supplementary
Table 2.
To investigate which pathways are important in hypoxia
signaling, we clustered the oxygen-regulated genes on the
basis of protein–protein interactions (Fig. 2a) and subse-
quently categorized the genes into KEGG pathways
important in angiogenesis (Table 2). The angiogenic
pathways that were significantly altered by prolonged
hypoxia in the presence of VEGF-A/TNFa included the
HIF-1 signaling pathway, and several metabolic, cell cycle
and amino acid biosynthesis pathways. When the upregu-
lated and the downregulated genes by hypoxia were clus-
tered separately and categorized into KEGG pathways, the
upregulated genes showed an enrichment within cytokine–
cytokine receptor interactions, such as TNFa, TGF-b and
MAPK signaling pathways, and several metabolic path-
ways, such as glycolysis/gluconeogenesis, and carbon-,
fructose- and mannose metabolism (Table 2; Fig. 2a). In
contrast, the downregulated genes were categorized mainly
in cell cycle, DNA replication and the p53 signaling
pathways (Table 2; Fig. 2a). Taken together, these data
show that 834 genes are significantly differentially regu-
lated in hypoxia. Many of the upregulated genes are enri-
ched in metabolic pathways, whereas many of the
downregulated genes are enriched in cell cycle pathways.
Identifying HIF-2a-regulated genes and pathways
HIF-2a silencing partially restored the endothelial sprout-
ing (see below, Fig. 5a) in long-term hypoxia. HIF-2a
mRNA was significantly silenced with si-RNA, while HIF-
1a mRNA was not affected (Supplementary Table 3). HIF-
3a mRNA, in contrast, was significantly downregulated
with an si-RNA of HIF-2a, but this is probably a non-
specific effect as scrambled si-RNA similarly decreased
HIF-3a mRNA expression (Supplementary Table 3). The
RNA-seq data revealed in total 6757 significantly
(FDR\ 5 %) differentially regulated genes upon HIF-2a
silencing compared with prolonged hypoxia (untrans-
fected). However, 33 % of these genes were also signifi-
cantly regulated by transfection with scrambled si-RNA
and were excluded for further analysis. Of the remaining
genes, 449 upregulated and 715 downregulated genes had
an absolute fold change of[1.5. The 25 most upregulated
Fig. 2 Significantly regulated genes by hypoxia or si-HIF-2a are
involved in metabolism or cell cycle. Genes that were differentially
regulated (FDR\ 5 %, absolute fold difference [1.5) in hypoxia
(a) or upon HIF-2a silencing (b) were clustered based on protein–
protein interactions. The nodes represent the proteins and a shared
function of the proteins are shown as interconnecting blue lines. The
thickness of these lines indicates the confidence of the association. All
genes (upper panels), or only the upregulated or the downregulated
genes (lower panels) were clustered based on GO biological processes
involved in metabolic or RNA/cell cycle pathways; genes involved in
these pathways are indicated in red. (Color figure online)
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and most downregulated genes upon HIF-2a silencing,
including HIF-2a mRNA (EPAS1), ranked on basis of fold
change, are shown in Table 3. The list of all HIF-2a-reg-
ulated genes can be found in Supplementary Table 4.
Clustering of all si-HIF-2a-regulated genes based on
protein–protein interactions is shown in Fig. 2b, and these
genes were subsequently categorized into KEGG pathways
important in angiogenesis (Table 4). In contrast to the
many downregulated genes by hypoxia that were involved
in RNA/cell cycle (Fig. 2a), the genes involved in cell
cycle, ribosome biogenesis and RNA transport were
upregulated upon HIF-2a silencing (Table 4; Fig. 2b).
Moreover, metabolic genes were upregulated in hypoxia
(Fig. 2a), but downregulated upon HIF-2a silencing
(Table 4; Fig. 2b). These findings indicate that 1164 genes
are significantly differentially regulated upon silencing of
HIF-2a with si-RNA. Opposite to the oxygen-regulated
genes, many of the si-HIF-2a upregulated genes are enri-
ched in cell cycle/RNA processes, while the si-HIF-2a
downregulated genes are involved in multiple metabolic
pathways.
Identification of genes that may regulate endothelial
sprouting in prolonged hypoxia
To identify genes that may be involved in the regulation of
endothelial sprouting during prolonged hypoxia, we set
multiple criteria in our RNA-seq data: (1) genes should be
significantly regulated (FDR\ 5 % and fold change[1.5)
in hypoxia, (2) genes should be significantly regulated
upon HIF-2a silencing but not by scrambled si-RNA, and
(3) genes should be regulated in opposite directions in
hypoxia and after si-HIF-2a. These criteria resulted in 51
genes (Table 5), as potential candidates that may regulate
endothelial sprouting into fibrin in hypoxia. Clustering of
the genes based on protein–protein interactions did not
reveal a significant enriched pathway.
Table 2 Hypoxia pathway analysis
All genes (834) Upregulated genes (501) Downregulated genes (333)
HIF-1 signaling pathway(5.7E-07) Cytokine–cytokine receptor interaction(3.8E-06) Cell cycle(5.8E-07)
p53 signaling pathway(9.3E-06) Glycolysis/gluconeogenesis(7.7E-05) p53 signaling pathway(1.0E-05)
Cytokine–cytokine receptor interaction(1.1E-04) HIF-1 signaling pathway(1.6E-04) HIF-1 signaling pathway(1.4E-03)
Cell cycle(3.1E-04) Biosynthesis of amino acids(2.3E-04) Glycine, serine and threonine
metabolism(3.4E-03)
Biosynthesis of amino acids(4.1E-04) TNF signaling pathway(8.9E-02) Homologous recombination(9.0E-03)
Glycolysis/gluconeogenesis(5.5E-04) Inflammatory mediator regulation of TRP
channels(1.7E-03)
Arginine and proline metabolism(1.3E-02)
Inflammatory mediator regulation of TRP
channels(1.2E-03)
Carbon metabolism(2.8E-03) VEGF signaling pathway(1.5E-02)
Cysteine and methionine metabolism(2.7E-03) Calcium signaling pathway(2.8E-03) DNA replication(1.8E-02)
FoxO signaling pathway(2.9E-03) Pentose phosphate pathway(3.0E-03) Biosynthesis of unsaturated fatty
acids(4.4E-02)
TNF signaling pathway(3.2E-03) Hedgehog signaling pathway(6.3E-03)
Glycine, serine and threonine
metabolism(4.0E-03)
Fructose and mannose metabolism(6.4E-03)
Proteoglycans in cancer(6.1E-03) FoxO signaling pathway(7.5E-03)
Carbon metabolism(7.1E-03) Cysteine and methionine metabolism(9.8E-03)
Pentose phosphate pathway(1.8E-02) Neuroactive ligand–receptor interaction(1.2E-02)
Calcium signaling pathway(2.1E-02) Galactose metabolism(3.3E-02)
Arginine and proline metabolism(2.5E-02) Proteoglycans in cancer(3.4E-02)
VEGF signaling pathway(2.9E-02) TGF-beta signaling pathway(3.5E-02)
Rap1 signaling pathway(3.3E-02) MAPK signaling pathway(3.6E-02)
Fructose and mannose metabolism(3.6E-02) NOD-like receptor signaling pathway(4.3E-02)
Cell adhesion molecules (CAMs)(4.4E-02) Glycosaminoglycan biosynthesis—keratan
sulfate(4.7E-02)
Hedgehog signaling pathway(4.7E-02) Apoptosis(4.8E-02)
Protein digestion and absorption(3.8E-02)
The KEGG pathways involved in angiogenesis or metabolism with a p value of\0.05 are shown. Significance per pathway is shown in
parenthesis
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To examine which of these genes played a role in
endothelial sprouting in hypoxia, an initial screening using
specific si-RNAs of these genes was performed with a pool
of four independent hMVEC donors. From this initial
screening, 13 genes were selected as positive candidates,
including 9 genes that were upregulated in hypoxia
(highlighted in red in Table 5) and therefore potential
inhibitors of sprouting, and 4 genes that were downregu-
lated in hypoxia and therefore possible stimulators of
angiogenesis (highlighted in green in Table 5). Taken
together, from the RNA-seq51 genes are significantly dif-
ferentially regulated in hypoxia and upon HIF-2a silencing
in opposite directions, but not by scrambled si-RNA.
Moreover, the initial screening using specific si-RNAs
reveals 13 genes that are selected as potential regulators of
angiogenesis.
Involvement of the 13 genes in regulating endothelial
sprouting
The changes in relative mRNA expression of the selected
genes were confirmed with quantitative real-time PCR
(Fig. 3a, b). The pattern of hypoxia down-/si-HIF-2a up-
regulated genes was consistently observed (Fig. 3a), but
the hypoxia up-/si-HIF-2a down-regulated genes were only
found in 2 out 4 genes and no differences were seen
between si-HIF-2a and Scr (Fig. 3b). Next, the role of the
13 selected genes from the initial screening in sprout for-
mation was investigated in independent hMVEC donors
instead of a pooled hMVEC batch, in short-term hypoxia,
prolonged hypoxia and normoxia. Through efficient knock
down of the mRNA with specific si-RNAs (Fig. 4a), we
found that silencing of ARRDC3, CDKN3, FAM189A2,
Table 3 Top 25 genes with significantly induced or repressed gene expression upon HIF-2a knock-down, but not upon scrambled si-RNA
transfection, in hypoxia-precultured hMVECs after VEGF-A/TNFa stimulation
Upregulated by si-HIF-2α Downregulated by si-HIF-2α
Gene Gene ID Fold Change Gene Gene ID Fold Change
1 PARP8 NM_001178055.1 4.1 1 MCHR1 NM_005297.3 0.11
2 HIST2H2BA NR_027337.1 3.5 2 EPAS1 NM_001430.4 0.15
3 HES4 NM_001142467.1 3.3 3 C20orf3 NM_020531.2 0.31







6 PTP4A3 NM_032611.2 2.7 6 ARRDC3 NM_020801.3 0.40
7 HOXD-AS2 NR_038435.1 2.7 7 KISS1 NM_002256.3 0.41
8 NEURL3 NM_001285485.1 2.6 8 NOVA1 NM_002515.2 0.41
9 ICAM4 NM_001544.4 2.5 9 FADS1 NM_013402.4 0.44
10 CRIP1 NM_001311.4 2.5 10 CA12 NM_001218.4 0.45
11 MYEOV NM_001293291.1 2.5 11 CTSO NM_001334.2 0.45
12 C6ORF141 NM_001145652.1 2.5 12 TIMP4 NM_003256.3 0.45
13 SPATS2L NM_015535.2 2.4 13 SLC39A10 NM_001127257.1 0.46







16 CDKN2A NM_000077.4 2.4 16 GMCL1P1 NR_003281.1 0.47
17 TRAF4 NM_004295.3 2.4 17 MMD NM_012329.2 0.47
18 TMEM91 NM_001098821.1 2.3 18 PCYOX1 NM_016297.3 0.47









21 HCP5 NR_040662.1 2.3 21 LOC643401 - 0.48
22 FBXO6 NM_018438.5 2.3 22 C7orf10 NM_001193311.1 0.49
23 MIR31HG NR_027054.1 2.2 23 CAMK4 NM_001744.5 0.49
24 NOP56 NM_006392.3 2.2 24 REPS2 NM_004726.2 0.49
25 PLEKHF1 NM_024310.4 2.2 25 PPARG NM_138712.3 0.49
The relative gene expression was compared with the gene expression of hMVEC precultured in hypoxia and stimulated with VEGF-A/TNFa
(n = 4 independent donors)
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MME, PLXNA4, PPARG, PTP4A3, RALGPS2 and
ZNF292 resulted in an increased sprouting of more than
25 % compared with scrambled si-RNA. Silencing of
SNX33 resulted in a decreased sprouting of more than
25 % compared with scrambled in short-term (7 days)
hypoxia (Fig. 4b, c).
Furthermore, we examined whether silencing of these
genes may restore sprouting in hMVECs in prolonged
hypoxia. By using a similar threshold of 25 % more
sprouting compared to the scrambled control, we deter-
mined that silencing of ARRDC3, MME, PPARG and
RALGPS2 partially restored sprouting in prolonged
hypoxia (Fig. 5a). Finally, we investigated whether these
genes also regulated endothelial sprouting under normoxic
conditions. Silencing of ARRDC3, CDKN3, FAM189A2,
MME, PLXNA4, PPARG, PTP4A3, RALGPS2 and
TM4SF18 resulted in an increased sprouting of more than
25 % compared with scrambled, and silencing of SNX33
resulted in a decreased sprouting of more than 25 %
compared with scrambled (Fig. 5b). Taken together, from
the 13 candidate genes, silencing of ARRDC3, MME,
PPARG and RALGPS2 increases sprouting more that 25 %
compared with scrambled in all conditions.
Discussion
This study identified HIF-2a-regulated genes that were
involved in endothelial sprouting during hypoxia and nor-
moxia and stimulated with VEGF-A/TNFa. Using genome-
wide RNA-sequencing, we found that only 51 genes out of
the *12,000 known genes that were expressed in
endothelial cells had an absolute fold change of[1.5 and
were significantly regulated (FDR\ 5 %) by both hypoxia
and after HIF-2a silencing. Of these 51 genes, 13 candidate
genes (ARRDC3, CA12, CDKN3, FAM189A2, MME,
Table 4 HIF-2a pathway analysis
All genes (1164) Upregulated genes (449) Downregulated genes (715)
Carbon metabolism(5.7E-04) Ribosome biogenesis in
eukaryotes(4.1E-03)
Fatty acid metabolism(4.0E-05)
Biosynthesis of unsaturated fatty acids(8.2E-04) Vitamin B6 metabolism (6.1E-03) Biosynthesis of unsaturated fatty acids(6.6E-05)
Fatty acid metabolism(1.3E-03) MAPK signaling pathway(6.6E-03) Metabolic pathways(9.4E-05)
Citrate cycle (TCA cycle)(4.1E-03) RNA transport(3.9E-02) Carbon metabolism(2.6E-04)
MAPK signaling pathway(4.1E-03) Cell cycle(4.1E-02) PPAR signaling pathway(2.7E-03)
Metabolic pathways(7.5E-03) Estrogen signaling pathway(4.5E-02) Citrate cycle (TCA cycle)(2.7E-03)
GnRH signaling pathway(9.5E-03) Regulation of actin cytoskeleton(7.3E-03)
p53 signaling pathway(1.1E-02) p53 signaling pathway(8.6E-03)
Oxytocin signaling pathway(1.2E-02) Axon guidance(1.2E-03)
Sphingolipid metabolism(1.5E-02) Osteoclast differentiation(1.2E-02)
cGMP-PKG signaling pathway(1.6E-02) Focal adhesion(1.3E-02)
Axon guidance(2.1E-02) Ether lipid metabolism(1.3E-02)
Vascular smooth muscle contraction(2.8E-02) Ribosome(1.6E-02)
Glycerophospholipid metabolism(3.2E-02) Fatty acid degradation(1.7E-02)
Propanoate metabolism(3.2E-02) Valine, leucine and isoleucine
degradation(1.9E-02)
Valine, leucine and isoleucine
degradation(3.6E-02)
Sphingolipid metabolism(2.4E-02)
PPAR signaling pathway(3.7E-02) Propanoate metabolism(2.5E-02)
Vitamin B6 metabolism(4.1E-02) Starch and sucrose metabolism(3.1E-02)
Wnt signaling pathway(4.1E-02) GnRH signaling pathway(3.4E-02)
Osteoclast differentiation(4.4E-02) Endocytosis(4.1E-02)
VEGF signaling pathway(4.7E-02) Oxytocin signaling pathway(4.4E-02)
Pantothenate and CoA biosynthesis(4.9E-02) Sulfur metabolism(4.7E-02)
Ras signaling pathway(4.8E-02)
Ubiquitin-mediated proteolysis(4.8E-02)
The KEGG pathways involved in angiogenesis or metabolism with a p value of\0.05 are shown. Significance per pathway is shown in
parenthesis
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PLXNA4, PPARG, PTP4A3, RALGPS2, SNX33,
TM4SF18, TMEM121, ZNF292) showed to regulate
endothelial sprouting in short-term and long-term hypoxia
and normoxia. Further examination showed that silencing
of ARRDC3, MME, PPARG and RALGPS2 partly restored
the prolonged hypoxia-induced inhibition of endothelial
sprouting.
Identifying oxygen- and HIF-2a-regulated genes
involved in sprouting during prolonged hypoxia
The RNA-sequencing showed that VEGF-A was 3.5-fold
induced during prolonged hypoxia. Although an increased
VEGF-A expression in response to hypoxia was published
before [4–6, 22–24, 29, 39], these studies only investigated
short-term hypoxia (16–48 h). Despite the increased
VEGF-A expression during prolonged hypoxia and the
stimulation with VEGF-A and TNFa during the sprouting
assay, the hMVECs were unable to form sprouts in pro-
longed hypoxia (Fig. 1). Moreover, the effects of pro-
longed hypoxia on VEGF receptors such as FLT1, KDR,
NRP1, NRP2 were small (\15 % reduction or induction),
which is probably caused by the presence of exogenous
VEGF-A (10 ng/mL) in both normoxia and hypoxia. Both
the increased VEGF-A expression and addition of excess
exogenous VEGF-A exclude that limited VEGF-A
availability causes reduced sprouting in prolonged hypoxia.
Therefore, hypoxia-responsive genes upon VEGF-A/TNFa
stimulation were explored in more detail.
The RNA-sequencing approach revealed 501 genes that
were significantly upregulated in response to prolonged
hypoxia. The top 10 of the genes with largest upregulation
include EGLN3, HIF3A and SLC2A1. Upregulation of
these genes in response to short-term hypoxia (16–72 h)
was also observed in microarrays using human endothelial
cells [4, 29] or tumor cells lines [22–24, 39]. In addition,
we identified 333 genes that were significantly downregu-
lated in response to prolonged hypoxia. The top 10 of the
genes with largest downregulation include RRM2, MYBL2
and HMOX1, which is in line with the short-term hypoxia
microarray studies [29].
Through silencing of HIF-2a with specific si-RNA, the
prolonged hypoxia-induced inhibition of endothelial cells
was partially restored. HIF-2a has often been studied in
human tumor cell lines and human cells without functional
HIF-1a [22–24, 27, 40, 41]. However, studies investigating
gene regulation of HIF-2a in human endothelial cells with
functional HIF-1a are absent. Our study examined HIF-2a-
target genes by silencing of HIF-2a with si-RNA in pro-
longed hypoxia, which had no effect on HIF-1a expression.
Upon silencing of HIF-2a, 449 genes were significantly
upregulated and 715 were significantly downregulated
Table 5 51 genes were selected from genome-wide RNA-sequencing
Gene Name
ACER2 NM_001010887.2 FER1L4 NR_119376.1 PTP4A3 NM_032611.2
ANXA3 NM_005139.2 LOC100506746 NR_038841.1 RALGPS2 NM_152663.4
ARRDC3 NM_020801.3 LOXL2 NM_002318.2 REPS2 NM_004726.2
BNIP3L NM_004331.2 MCHR1 NM_005297.3 SDSL NM_138432.3
C16orf59 NM_025108.2 MIR31HG NM_005297.3 SLC38A4 NM_018018.4
CA12 NM_001218.4 MME NM_000902.3 SNX33 NM_153271.1
CACNA1C NM_199460.3 NLRC3 NM_178844.3 TIMP4 NM_003256.3
CCL28 NM_148672.3 NPR2 NM_003995.3 TM4SF18 NM_138786.3
CCNG2 NM_004354.2 P4HA1 NM_000917.3 TMEM121 NM_025268.2
CDKN2A NM_000077.4 PCDH10 NM_032961.2 TNFRSF10B NM_003842.4
CDKN3 NM_005192.3 PDXP NM_020315.4 TRAP1 NM_016292.2
DPY19L3 NM_207325.2 PLOD2 NM_182943.2 TSPAN2 NM_005725.5
ENO3 NM_001976.4 PLXNA4 NM_020911.1 WDR66 NM_144668.5
FAM102B NM_001010883.2 PMEPA1 NM_020182.4 WNT5A NM_003392.4
FAM115C NM_001130025.1 PODXL NM_001018111.2 XRCC6BP1 NM_033276.3
FAM160A1 NM_001109977.1 PPARG NM_138712.3 ZCWPW2 NM_001040432.3
FAM189A2 NM_004816.3 PRRX1 NM_006902.4 ZNF292 NM_015021.1
Fifty-one genes were significantly differentially regulated in hypoxia and upon HIF-2a silencing in opposite directions, but not by transfection
with scrambled si-RNA. Through an initial sprouting screening, 13 genes were selected that altered endothelial sprouting upon silencing; these
genes are highlighted in bolt. The genes that were upregulated in prolonged hypoxia are indicated in red, and the genes that are downregulated in
prolonged hypoxia are indicated in green
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compared with the gene expression in normoxia. Genes
that were significantly regulated upon transfection with
scrambled si-RNA in prolonged hypoxia were excluded
from further analysis. Among the HIF-2a-regulated genes
are LOXL2, RAB42 and MMP17, which have been iden-
tified as HIF-2a-target genes in short-term hypoxia
[24, 27, 41].
It should be mentioned that—because of the transient
nature of si-RNA transfection—si-RNA was added after
the initial 2-week hypoxic preincubation at the onset of the
1-week evaluation of sprouting. Repeated transfections
were avoided to limit cell damage or unwanted activation.
Notwithstanding this limitation, our data clearly show
partial rescue of prolonged hypoxia-induced inhibition of
endothelial tube formation, but an underestimation of the
effect of si-HIF-2a cannot be excluded yet.
Metabolic pathways are increased in hypoxia
and decreased by si-HIF-2a
KEGG pathway analysis revealed that the upregulated
genes in long-term hypoxia were enriched in several
metabolic pathways, such as glycolysis/gluconeogenesis,
carbon-, fructose- and mannose metabolism (Table 2).
During hypoxia, lack of oxygen prevents optimal func-
tioning of the electron transport chain. However, inhibition
of mitochondrial ATP production has very little effect on
the endothelial cellular ATP level [42] and did not affect
endothelial sprouting at normoxic conditions [43] (our own
unpublished observations). As energy is mainly produced
during glycolysis, it is functional that the glycolysis path-
way is upregulated during hypoxia [28, 29, 44, 45]. It has
been suggested that glycolysis genes are dependent on HIF-
Fig. 3 Relative mRNA expression of 13 genes that were selected
after the screening. hMVECs were cultured in normoxia for 14 days,
not transfected and stimulated for 24 h with VEGF-A/TNFa in
normoxia [Un (20 % O2), white bar] or cultured in prolonged hypoxia
for 14 days, not transfected and stimulated for 24 h with VEGF-A/
TNFa in hypoxia [Un (1 % O2), black bar]. Moreover, hMVECs were
cultured in prolonged hypoxia for 14 days, transfected with si-HIF-2a
[si-H2 (1 % O2), light gray bar] or scrambled [scr (1 % O2), dark
gray bar] and stimulated for 24 h with VEGF-A/TNFa in hypoxia.
mRNA was isolated for analysis by qRT-PCR, and the relative
mRNA levels of the 13 candidate genes were expressed as mean fold
change with SEM (n = 4 independent donors). Data were normalized
to 1 % O2. a Nine genes that were upregulated in the RNA-seq
analyses. b Four genes that were downregulated in the RNA-seq
analyses. For statistical analysis, two-way ANOVA with Bonferroni
post hoc test was used (*p\ 0.05; ***p\ 0.001)
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1 and not on HIF-2 [22]. Many of metabolic genes were
significantly downregulated in our HIF-2a-depleted
hMVECs (Table 4). Although the HIF-2a-regulated meta-
bolic pathways include fatty acid- and carbon metabolism,
glycolysis genes are not significantly altered by silencing
of HIF-2a.
Cell cycle pathway is decreased in hypoxia
and increased upon si-HIF-2a
In contrast to the upregulated genes, the downregulated
genes in long-term hypoxia were enriched within cell cycle
and DNA replication pathways. This would suggest that
endothelial cell proliferation was decreased in hypoxia.
Although it has been shown that genes involved in cell
cycle, DNA replication and DNA repair were also down-
regulated genes in response to short-term hypoxia in
endothelial [29, 44] or tumor cells [4], we did not find
significant differences in proliferation rates in hMVECs
precultured for 14 days in hypoxia or normoxia [20].
To our surprise, many cell cycle genes were upregulated
in HIF-2a-depleted hMVECs, suggesting an increased
proliferative capacity of the hMVECs. However, under our
experimental conditions, the hMVECs are stimulated with
TNFa, which is shown to inhibit proliferation in endothe-
lial cells [21]. Notwithstanding, the pathway analysis
Fig. 4 Transfection efficiency of candidate genes and effect of their
silencing on endothelial sprouting in short-term hypoxia. hMVECs
were precultured at 20 % oxygen and silenced with one of the 13
genes selected from the screening. a mRNA was isolated to analyze
the knock-down efficiency of si-RNA. The knock-down efficiency
was expressed as mean with range (n = 2 independent donors), and
scrambled transfection was set as 100 % (horizontal line). b hMVECs
were seeded on top of fibrin matrices before transfection with si-
RNA. Subsequently, the hMVECs were stimulated with the combi-
nation of VEGF-A and TNFa and transferred to hypoxia. Tube length
of hMVECs 7 days after stimulation with VEGF-A/TNFa was
quantified by using Optimas software and expressed as percentage
of Scrambled with SEM (n = 3 independent donors, each in
triplicate). c Representative photographs are shown of hMVECs
7 days after seeding and stimulation with VEGF-A/TNFa. The scale
bars represent 1 mm. Photographs are focused on the sprouts. The
genes that were upregulated in prolonged hypoxia are expressed as
black bars, and the genes that were downregulated in prolonged
hypoxia are expressed as white bars. For statistical analysis, one-way
ANOVA with Bonferroni post hoc test was used (**p\ 0.01;
***p\ 0.001)
50 Angiogenesis (2017) 20:39–54
123
indicated that hypoxia, through HIF-2a, induced metabolic
reprogramming and preservation of energy through
decreased cell cycle and DNA replication.
Are ARRDC3, PPARc, RALGPS2, and MME
involved in endothelial sprouting?
Combining the data of the oxygen- and HIF-2a-regulated
genes, only 51 genes overlapped in opposite direction.
These include a few known hypoxia-responsive genes [24],
such as BNIP3L, LOXL2, PPARG and P4HA1. Only
LOXL2 was described in the literature to be a HIF-2a-
regulated gene [24]. However, further screening of the role
of LOXL2 in endothelial sprouting showed that LOXL2
did not affect endothelial sprouting in hypoxia (Table 5).
The tube formation screening revealed 13 genes that
influenced sprouting during short-term hypoxia, but only 4
of these 13 genes (ARRDC3, MME, PPARc and
RALGPS2) also regulated endothelial sprout formation
during prolonged hypoxia (compare Fig. 4b and Fig. 5a).
It is suggested that arrestin domain containing 3
(ARRDC3), also identified as TLIMP, plays a role in
membrane protein internalization, like most members of
the arrestin family [46–48]. Its expression was found in
several human cancer cell lines and multiple human tis-
sues, and not in endothelial cells, but is—surprisingly—
induced by PPARc [46]. In mammary tumor cells,
repression of ARRDC3 enhanced the proliferation and
migration [49].
Peroxisome proliferator-activated receptor gamma
(PPARG) is expressed in many tissues with highest
expression in adipose tissue and is mainly involved in lipid
and glucose metabolism [50]. PPARG is also expressed in
endothelial cells and is upregulated in response to short-
term hypoxia (24–48 h) [4, 29]. Stimulation of PPARc by
agonists inhibited bFGF- and VEGF-stimulated angiogen-
esis, endothelial cell migration and proliferation [51–53].
Moreover, these PPARc agonists inhibited tumor cell
proliferation and angiogenesis in vivo [52]. However, in
the lungs, loss of PPARc results in decreased angiogenesis
[54, 55].
Ral GEF with PH domain and SH3 binding motif 2 or
RalA exchange factor (RALGPS2) is a member of the Ral
GEF family of proteins. Unlike most Ral GEF proteins,
RALGPS2 has a Ras-independent function and is probably
involved in actin polymerization and cytoskeleton organi-
zation through binding to actin filaments [56]. RALGPS2
has highest expression in the testis or brain [56, 57]. It is
suggested that RALGPS2 functions as an inhibitor of RalA
signaling and thereby decreases tumor cell proliferation
and induces apoptosis [58, 59]. The role of RALGPS2 in
endothelial cells is probably different, because no cell
death was observed during our 7-day tube formation assay.
It is known that membrane metalloendopeptidase
(MME) plays a role during angiogenesis [60, 61]. MME,
also known as neutral endopeptidase or neprilysin (NEP),
CD10 or common acute lymphoblastic leukemia antigen
(CALLA), is a zinc-dependent metalloprotease enzyme
involved in the cleavage and inactivation of certain peptide
hormones involved in signal transduction [61, 62]. Its
expression has been found in many tumor cells [63] and
several tissues including epithelial and endothelial cells
Fig. 5 Effect of silencing candidate genes on endothelial sprouting in
prolonged hypoxia and normoxia. hMVECs were precultured at 1 %
oxygen (a) or 20 % oxygen (b) and silenced with one of the 13 genes
selected from the screening. hMVECs were seeded on top of fibrin
matrices before transfection with si-RNA. Subsequently, the
hMVECs were stimulated with the combination of VEGF-A and
TNFa. Tube length of hMVECs 7 days after stimulation with VEGF-
A/TNFa was quantified by using Optimas software and expressed
percentage of Scrambled with SEM (n = 3 independent donors, each
in triplicate). The genes that were upregulated in prolonged hypoxia
are expressed as black bars, and the genes that were downregulated in
prolonged hypoxia are expressed as white bars. For statistical
analysis, one-way ANOVA with Bonferroni post hoc test was used
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[64, 65]. mRNA expression was increased in lung cancer
cells and lung fibroblasts in response to hypoxia [28], but
decreased in human pulmonary arterial smooth muscle
cells, murine lungs [66] or murine lung and renal homo-
genates [67]. Moreover, MME inhibits endothelial FGF-2-
stimulated angiogenesis, proliferation and migration
[60, 61]. In our study, we showed that MME also inhibits
VEGF-stimulated angiogenesis.
Conclusion
In conclusion, this study identified four novel HIF-2a tar-
get genes that inhibit endothelial sprouting during pro-
longed hypoxia in vitro. Of these four genes, PPARc and
MME have previously been linked to angiogenesis, while
ARRDC3 and RALGPS2 only have been shown to influ-
ence cell proliferation. PPARG is an interesting gene for
further investigation; it induces the expression of ARRDC3
and plays a role in both angiogenesis and metabolism. In
particular, the metabolism pathway was enriched among
the upregulated genes in response to hypoxia. This suggests
that PPARc and ARRDC3 are potential targets to restore
reduced neovascularization in several pathological condi-
tions, such as diabetic or other chronic ischemic wounds, or
for improvement of vascularization of implanted tissue-
engineered scaffolds.
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